TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04459611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: 260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: 260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
Study: NCT00254982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
Study: NCT03956303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine %0.5
Description: Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine Heavy 40
Description: Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine Heavy 60
Description: Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine Heavy 80
Description: Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl
Study: NCT00317239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate tablets
Description: 325 mg/TID x 8 weeks
Study: NCT01347099

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Support therapy on Internet
Description: Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
Study: NCT04792541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HY containing gel; GUM® Afta Clear Gel, Sunstar
Study: NCT01493531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Tablets
Study: NCT03091894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
Study: NCT00317239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
Study: NCT01799174

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UVA-1 Phototherapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study: NCT03333460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
Study: NCT02369627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid HIV Self-Test (OraQuick® In-home HIV Test)
Description: The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Home-Based HIV Test (Home Access Express)
Description: The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community/Medical-Based HIV Test
Description: The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
Study: NCT00002594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given IV
Study: NCT04792541

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Study: NCT00002594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study: NCT03373877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Dosing will be in accordance with current package insert and dose subject was on during study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Dosing will be in accordance with current package insert and dose subject was on during study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Dosing will be in accordance with current package insert and dose subject was on during study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Dosing will be in accordance with current package insert and dose subject was on during study entry.
Study: NCT03485560

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ACE CSD
Description: Topical application of the ACE CSD 4 times daily.
Study: NCT02590497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo diffusion weighted MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Undergo gadolinium-enhanced MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Tissue genetic analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo gadolinium-enhanced MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo 3D volumetric T1-weighted sequence

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo FLAIR sequence

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Magnetic Resonance Imaging
Description: Undergo perfusion MRI
Study: NCT03004638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6012 40 mg
Description: Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
Study: NCT02065895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIGH error
Description: Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIGH error
Description: Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
Study: NCT00002594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT05288673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.
Study: NCT02360709

Intervention type: DEVICE
Intervention: CRE8 sirolimus-eluting stent
Description: The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
Study: NCT05288673

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).
Study: NCT01016821

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
Study: NCT04413669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: white light bronchoscopy & autofluorescence bronchoscopy
Description: White light bronchoscopy and autofluorescence bronchoscopy were carried out，and Take a biopsy for abnormal bronchial mucosa
Study: NCT03113825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Imaging device
Description: Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-620
Description: AVB-620 will be administered IV before the surgical procedure.
Study: NCT03843255

Intervention type: OTHER
Intervention: Part 1: DCM Cohort
Description: Patients with a confirmed diagnosis of DCM will have samples that undergo whole genome sequencing and biomarker analysis

Intervention type: OTHER
Intervention: Part 2: Heritable CV Diseases and Family Members
Description: Biomarker analysis will be undertaken on samples
Study: NCT00176852

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan, Fludarabine, ATG, TLI
Description: Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Cyclophosphamide, ATG, GCSF
Description: Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC \>2500 x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath, Fludarabine, Cyclophosphamide
Description: Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 300 cGY Day -1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 300 cGY Day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Given Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Given Day 0
Study: NCT01220089

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard maintenance
Description: Participants will receive written materials in months 7-18

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensified maintenance
Description: Participants will continue with in-person counseling visits in months 7-18
Study: NCT01373476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qideng Mingmu capsule
Description: High dosage group (4 Qideng Mingmu capsules each time): 4#, po, tid,24 weeks; Middle dosage group (2 Qideng Mingmu capsules plus 2 placebos each time):4#, po, tid,24 weeks;Low dosage group (1 Qideng Mingmu capsule plus 2 placebos each time):3#, po, tid,24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo group (4 placebos each time):4#, po, tid,24 weeks.
Study: NCT01501201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric By-Pass
Description: Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimized medical management
Description: group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
Study: NCT00411801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uniplas
Description: Uniplas will be provided frozen in sterile plastic bags.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cryosupernatant plasma
Description: Cryosupernatant plasma will be provided frozen in sterile plastic bags.
Study: NCT01202994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Flutemetamol
Description: All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).~For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.~The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images.
Study: NCT02964052

Intervention type: OTHER
Intervention: Brain CT imaging
Description: Investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. Investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.
Study: NCT04009473

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SEGOVA procedure
Description: SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
Study: NCT00681577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, KOC1, VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
Study: NCT05799859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of coronally advanced flap (CAF) and collagen matrix (CM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).
Study: NCT04499235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Topical mometasone furoate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate
Description: Topical mometasone furoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKST4290
Description: Oral AKST4290

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study: NCT00736931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Brivaracetam 10 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: 500mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam
Description: lorazepam 2 mg over encapsulated tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study: NCT02071758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3 + SLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3 + SLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3 + GLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3 + GLA-SE
Study: NCT01989195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
Description: EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT~* CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)~* CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI
Study: NCT03497988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
Study: NCT04611048

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermal QST (CDT, WDT, CPT, HPT) with the method of limits
Description: The testing will be carried out using the classical method of limits, i.e. a continuous heating/cooling stimulus will be applied to the skin at a rate of 1°C/s, until the subject signals that he/she felt the targeted sensation by pressing a button (Rolke, Baron, et al., 2006). The temperature reached by the time the subject pressed the button will be considered the threshold. Baseline temperature will be set at 32°C. The stimuli will not go lower than 0°C and higher than 50°C.
Study: NCT03004638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6012 120 mg
Description: Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
Study: NCT03537924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT03793881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Strategy
Description: Counseling based on dietary goals and mindfulness techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Prescription
Description: Dietary prescription according to guidelines.
Study: NCT04174092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completing self-questionnaires
Description: completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completing self-questionnaires
Description: completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completing self-questionnaires
Description: completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism
Study: NCT00793416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shunt flow detection
Description: Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
Study: NCT02824913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-321 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-321 Ophthalmic Solution placebo
Study: NCT03900260

Intervention type: DEVICE
Group type: OTHER
Intervention: Softec HP1 Intraocular Lens
Description: The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.